miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The companies expect the deal to close next quarter.

A syndicate of existing and new miRagen investors is to invest about $40 million in the company just prior to the merger's close. The syndicate includes Fidelity, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO, MP Healthcare Venture Management, MRL Ventures and Remeditex Ventures...